Prof Erich Schlick, M.D
Prof Dr Erich Schlick has over 25 years of experience in the healthcare sector. Erich Schlick spent five years at the US National Cancer Institute, and over 15 years with BASF Pharma, including ten years as the executive board member responsible for worldwide R&D. He established BASF Pharma’s immunology business, and its U.S. biotech centre specializing in immunology and monoclonal antibodies.
From 2001 to September 2005, Erich Schlick worked for 3i, in his last position as head of 3i’s Healthcare Team in Germany and as Deputy Head of 3i Healthcare Worldwide. In September 2005, he joined Wellington Partners as a General Partner of their Life Science Fund.
Erich Schlick is a member of AACR, AAI, Deutsche Krebsgesellschaft, German Asssociation of Pharmacologists and the editorial board of JImmunpharm. He sits on the supervisory boards of ZI (University of Heidelberg), a WHO reference centre for psychiatry and of Paion AG (Aachen, Germany), a public company specialized in treating stroke patients.
Erich Schlick is a qualified medical doctor and a professor of immunopharmacology at the University of Heidelberg.